Last Updated: July 4, 2026

ONZETRA Drug Patent Profile

Name: ONZETRA Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Onzetra, and when can generic versions of Onzetra launch?

Onzetra is a drug marketed by Currax and is included in one NDA. There are twelve patents protecting this drug.

The generic ingredient in ONZETRA is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Onzetra

A generic version of ONZETRA was approved as sumatriptan succinate by HIKMA on February 6^th, 2009.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ONZETRA?
What are the global sales for ONZETRA?
What is Average Wholesale Price for ONZETRA?

Summary for ONZETRA

US Patents:	0
Applicants:	1
NDAs:	1
Drug Prices:	Drug price information for ONZETRA
What excipients (inactive ingredients) are in ONZETRA?	ONZETRA excipients list
DailyMed Link:	ONZETRA at DailyMed

Drug patent expirations by year for ONZETRA

US Patents and Regulatory Information for ONZETRA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes	8,875,704	⤷ Start Trial	Y			⤷ Start Trial
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes	10,076,614	⤷ Start Trial	Y			⤷ Start Trial
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes	10,478,574	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.